Jinsong Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3946717/publications.pdf

Version: 2024-02-01

160 papers	13,434 citations	17405 63 h-index	24915 109 g-index
164 all docs	164 docs citations	164 times ranked	22326 citing authors

#	Article	IF	Citations
1	Guidelines and definitions for research on epithelialâ€“mesenchymal transition. Nature Reviews Molecular Cell Biology, 2020, 21, 341-352.	16.1	1,195
2	Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by Î²-phenylethyl isothiocyanate. Cancer Cell, 2006, 10, 241-252.	7.7	994
3	The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nature Medicine, 2004, 10, 1251-1256.	15.2	463
4	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine, 2018, 24, 556-562.	15.2	372
5	Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism, 2016, 24, 685-700.	7.2	293
6	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16472-16477.	3.3	292
7	Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Science Translational Medicine, 2017, 9, .	5.8	286
8	Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nature Medicine, 2005, 11, 531-537.	15.2	265
9	A Genetically Defined Model for Human Ovarian Cancer. Cancer Research, 2004, 64, 1655-1663.	0.4	259
10	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell, 2014, 26, 77-91.	7.7	252
11	Activated Signal Transducer and Activator of Transcription (STAT) 3. Cancer Research, 2004, 64, 3550-3558.	0.4	239
12	Mitochondrial Manganese-Superoxide Dismutase Expression in Ovarian Cancer. Journal of Biological Chemistry, 2005, 280, 39485-39492.	1.6	235
13	Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. International Journal of Cancer, 2007, 120, 81-90.	2.3	180
14	Mechanisms of nuclear content loading to exosomes. Science Advances, 2019, 5, eaax8849.	4.7	176
15	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications, 2017, 8, 310.	5.8	169
16	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell, 2019, 35, 851-867.e7.	7.7	156
17	CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis. Clinical Cancer Research, 2010, 16, 3875-3886.	3.2	152
18	FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 2018, 9, 2923.	5.8	151

#	Article	IF	Citations
19	ALDH1 expression correlates with favorable prognosis in ovarian cancers. Modern Pathology, 2009, 22, 817-823.	2.9	139
20	MiRâ€182 overexpression in tumourigenesis of highâ€grade serous ovarian carcinoma. Journal of Pathology, 2012, 228, 204-215.	2.1	138
21	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Molecular Cell, 2018, 69, 279-291.e5.	4.5	138
22	Cancer-Associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of Epithelial Ovarian Cancer. Neoplasia, 2011, 13, 393-405.	2.3	136
23	HMGA2 Overexpression-Induced Ovarian Surface Epithelial Transformation Is Mediated Through Regulation of EMT Genes. Cancer Research, 2011, 71, 349-359.	0.4	132
24	Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLoS Biology, 2012, 10, e1001326.	2.6	128
25	Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). Journal of Translational Medicine, 2004, 2, 23.	1.8	127
26	CD133 expression associated with poor prognosis in ovarian cancer. Modern Pathology, 2012, 25, 456-464.	2.9	123
27	Activation of Antioxidant Pathways in Ras-Mediated Oncogenic Transformation of Human Surface Ovarian Epithelial Cells Revealed by Functional Proteomics and Mass Spectrometry. Cancer Research, 2004, 64, 4577-4584.	0.4	120
28	The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 2006, 107, 2730-2740.	2.0	119
29	Validation of tissue microarray technology in ovarian carcinoma. Modern Pathology, 2004, 17, 790-797.	2.9	112
30	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications, 2014, 5, 5092.	5.8	112
31	Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene, 2003, 22, 5694-5701.	2.6	110
32	Stanniocalcin 1 and Ovarian Tumorigenesis. Journal of the National Cancer Institute, 2010, 102, 812-827.	3.0	107
33	Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer. Current Cancer Drug Targets, 2019, 19, 360-367.	0.8	107
34	Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2. Clinical Cancer Research, 2010, 16, 3171-3181.	3.2	106
35	Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Research, 2017, 77, 2903-2913.	0.4	106
36	The dualistic origin of human tumors. Seminars in Cancer Biology, 2018, 53, 1-16.	4.3	105

#	Article	IF	Citations
37	2â€²-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	5.8	103
38	Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression. Journal of Biological Chemistry, 2004, 279, 4339-4345.	1.6	101
39	Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene, 2021, 40, 3533-3547.	2.6	101
40	Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Molecular Cancer Therapeutics, 2009, 8, 2036-2045.	1.9	99
41	Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth. Molecular Pharmaceutics, 2010, 7, 775-785.	2.3	94
42	Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell, 2015, 28, 610-622.	7.7	94
43	miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget, 2014, 5, 10816-10829.	0.8	91
44	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	2.9	90
45	Ovarian cancer: pathology, biology, and disease models. Frontiers in Bioscience - Landmark, 2009, Volume, 2089.	3.0	88
46	Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. International Journal of Cancer, 2014, 134, 508-518.	2.3	84
47	Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer, 2006, 106, 1925-1932.	2.0	83
48	Biological Significance of Prolactin in Gynecologic Cancers. Cancer Research, 2009, 69, 5226-5233.	0.4	83
49	Identification of a Small Molecule with Synthetic Lethality for K-Ras and Protein Kinase C Iota. Cancer Research, 2008, 68, 7403-7408.	0.4	80
50	Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clinical Chemistry, 2019, 65, 674-683.	1.5	77
51	Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene, 2003, 22, 2396-2404.	2.6	76
52	PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Modern Pathology, 2009, 22, 1243-1250.	2.9	76
53	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports, 2016, 15, 1493-1504.	2.9	75
54	The Differential Role of L1 in Ovarian Carcinoma and Normal Ovarian Surface Epithelium. Cancer Research, 2008, 68, 1110-1118.	0.4	74

#	Article	IF	Citations
55	Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nature Communications, 2016, 7, 11363.	5.8	74
56	Interleukin-1Î² Promotes Ovarian Tumorigenesis through a p53/NF-ÎºB-Mediated Inflammatory Response in Stromal Fibroblasts. Neoplasia, 2013, 15, 409-IN18.	2.3	73
57	Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death and Disease, 2017, 8, e3070-e3070.	2.7	72
58	CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers. Human Pathology, 2009, 40, 252-258.	1.1	71
59	iTRAQ-Based Proteomic Analysis of Polyploid Giant Cancer Cells and Budding Progeny Cells Reveals Several Distinct Pathways for Ovarian Cancer Development. PLoS ONE, 2013, 8, e80120.	1.1	70
60	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Letters, 2019, 442, 464-474.	3.2	70
61	The â€œlife codeâ€: A theory that unifies the human life cycle and the origin of human tumors. Seminars in Cancer Biology, 2020, 60, 380-397.	4.3	70
62	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports, 2020, 31, 107502.	2.9	69
63	Inhibition of miR-328â€“3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer. Cancer Research, 2019, 79, 2314-2326.	0.4	68
64	Activation of KLF8 Transcription by Focal Adhesion Kinase in Human Ovarian Epithelial and Cancer Cells. Journal of Biological Chemistry, 2008, 283, 13934-13942.	1.6	67
65	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis, 2007, 28, 174-182.	1.3	62
66	PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival. Cancer Research, 2008, 68, 9302-9310.	0.4	62
67	Gliomatosis peritonei: a clinicopathologic and immunohistochemical study of 21 cases. Modern Pathology, 2015, 28, 1613-1620.	2.9	60
68	Expression of the Tumor Suppressor Gene ARHI in Epithelial Ovarian Cancer Is Associated with Increased Expression of p21WAF1/CIP1 and Prolonged Progression-Free Survival. Clinical Cancer Research, 2004, 10, 6559-6566.	3.2	59
69	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.4	59
70	Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression Is Lost in Ovarian and Breast Cancers. Methods in Enzymology, 2006, 407, 455-468.	0.4	58
71	Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. Human Pathology, 2012, 43, 1405-1412.	1.1	58
72	Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Letters, 2013, 333, 205-212.	3.2	58

#	Article	IF	Citations
73	Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biology and Therapy, 2015, 16, 1548-1556.	1.5	57
74	Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Modern Pathology, 2004, 17, 75-80.	2.9	55
75	AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Modern Pathology, 2011, 24, 836-845.	2.9	54
76	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clinical Cancer Research, 2017, 23, 1945-1954.	3.2	54
77	HMGA2: A Potential Biomarker Complement to P53 for Detection of Early-stage High-grade Papillary Serous Carcinoma in Fallopian Tubes. American Journal of Surgical Pathology, 2010, 34, 18-26.	2.1	53
78	Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 2404-2413.	3.2	52
79	Inflammation: A hidden path to breaking the spell of ovarian cancer. Cell Cycle, 2009, 8, 3107-3111.	1.3	52
80	Overexpression of the thymosin Î²-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis. Oncogene, 2001, 20, 6700-6706.	2.6	51
81	The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. Genes and Cancer, 2013, 4, 460-475.	0.6	51
82	Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute, 2016, 108, djv426.	3.0	51
83	Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clinical Cancer Research, 2003, 9, 3660-6.	3.2	51
84	Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Human Pathology, 2013, 44, 2373-2384.	1.1	50
85	Analogues and Derivatives of Oncrasin-1, a Novel Inhibitor of the C-Terminal Domain of RNA Polymerase II and Their Antitumor Activities. Journal of Medicinal Chemistry, 2011, 54, 2668-2679.	2.9	49
86	miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget, 2016, 7, 25930-25948.	0.8	49
87	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 2017, 8, 96496-96505.	0.8	49
88	VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. American Journal of Translational Research (discontinued), 2013, 5, 336-46.	0.0	48
89	Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Modern Pathology, 2006, 19, 1414-1420.	2.9	45
90	Tumor necrosis factor-Î± and interferon-Î³ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFÎºB. Oncotarget, 2016, 7, 14871-14884.	0.8	44

#	Article	IF	Citations
91	REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle, 2009, 8, 780-786.	1.3	43
92	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	2.9	43
93	RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy, 2018, 14, 637-653.	4.3	43
94	miR-106a Represses the Rb Tumor Suppressor p130 to Regulate Cellular Proliferation and Differentiation in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2013, 11, 1314-1325.	1.5	42
95	Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Letters, 2012, 326, 176-182.	3.2	40
96	Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells. Experimental Cell Research, 2012, 318, 1641-1648.	1.2	39
97	Carcinoma of the urethra. Human Pathology, 2018, 72, 35-44.	1.1	37
98	Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle, 2012, 11, 2107-2113.	1.3	36
99	Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opinion on Therapeutic Targets, 2015, 19, 1307-1317.	1.5	36
100	Expression and Function of Androgen Receptor Coactivator p44/Mep50/WDR77 in Ovarian Cancer. PLoS ONE, 2011, 6, e26250.	1.1	35
101	Up-regulation of Tumor Susceptibility Gene 101 Protein in Ovarian Carcinomas Revealed by Proteomics Analyses. Molecular and Cellular Proteomics, 2007, 6, 294-304.	2.5	34
102	<scp>RAS</scp> promotes tumorigenesis through genomic instability induced by imbalanced expression of Auroraâ€A and <scp>BRCA2</scp> in midbody during cytokinesis. International Journal of Cancer, 2013, 133, 275-285.	2.3	34
103	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes and Cancer, 2016, 7, 60-72.	0.6	34
104	Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene, 2005, 24, 6174-6184.	2.6	32
105	RASâ€Mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB Journal, 2006, 20, 497-499.	0.2	32
106	RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases, 2011, 2, 202-210.	0.7	32
107	CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Human Pathology, 2013, 44, 1882-1889.	1.1	32
108	B7-H4 expression in ovarian serous carcinoma: a study of 306 cases. Human Pathology, 2016, 57, 1-6.	1.1	32

#	Article	IF	Citations
109	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports, 2017, 21, 2785-2795.	2.9	32
110	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research, 2021, 27, 6354-6365.	3.2	31
111	Overexpression of the Î² Subunit of Human Chorionic Gonadotropin Promotes the Transformation of Human Ovarian Epithelial Cells and Ovarian Tumorigenesis. American Journal of Pathology, 2011, 179, 1385-1393.	1.9	30
112	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis, 2021, 10, 65.	2.1	30
113	Epithelial ovarian cancer: Focus on genetics and animal models. Cell Cycle, 2009, 8, 731-735.	1.3	28
114	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS ONE, 2015, 10, e0131833.	1.1	28
115	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Reports, 2021, 34, 108726.	2.9	27
116	A Fraction of CD133+ CNE2 Cells Is Made of Giant Cancer Cells with Morphological Evidence of Asymmetric Mitosis. Journal of Cancer, 2015, 6, 1236-1244.	1.2	26
117	The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochemical and Biophysical Research Communications, 2005, 336, 952-960.	1.0	25
118	Polyploid giant cancer cells: An emerging new field of cancer biology. Seminars in Cancer Biology, 2022, 81, 1-4.	4.3	25
119	Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway. BMC Cancer, 2016, 16, 582.	1.1	24
120	Protein citrullination as a source of cancer neoantigens. , 2021, 9, e002549.		24
121	The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Seminars in Cancer Biology, 2022, 81, 132-144.	4.3	23
122	Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. International Journal of Clinical and Experimental Pathology, 2014, 7, 848-57.	0.5	23
123	Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. IScience, 2022, 25, 103923.	1.9	23
124	Inhibiting JNK Dephosphorylation and Induction of Apoptosis by Novel Anticancer Agent NSC-741909 in Cancer Cells. Journal of Biological Chemistry, 2009, 284, 16948-16955.	1.6	22
125	Upregulation HOXA10 homeobox gene in endometrial cancer: role in cell cycle regulation. Medical Oncology, 2014, 31, 52.	1.2	22
126	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle, 2010, 9, 140-146.	1.3	21

#	Article	IF	Citations
127	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research, 2014, 16, 3417.	2.2	21
128	Activation of Sterile20-Like Kinase 1 in Proteasome Inhibitor Bortezomibâ€“Induced Apoptosis in Oncogenic K-ras-Transformed Cells. Cancer Research, 2006, 66, 6072-6079.	0.4	19
129	Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions. Archives of Pathology and Laboratory Medicine, 2016, 140, 148-152.	1.2	19
130	GATA6: a new predictor for prognosis in ovarian cancer. Human Pathology, 2019, 86, 163-169.	1.1	19
131	The Homeoprotein DLX4 Stimulates NF-Î°B Activation and CD44-Mediated Tumorâ€“Mesothelial Cell Interactions in Ovarian Cancer. American Journal of Pathology, 2015, 185, 2298-2308.	1.9	18
132	Cytoplasmic SIRT1 inhibits cell migration and invasion by impeding epithelialâ€“mesenchymal transition in ovarian carcinoma. Molecular and Cellular Biochemistry, 2019, 459, 157-169.	1.4	18
133	MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology and Oncology, 2016, 9, 112.	6.9	17
134	Giant cells: Linking McClintockâ€™s heredity to early embryogenesis and tumor origin throughout millennia of evolution on Earth. Seminars in Cancer Biology, 2022, 81, 176-192.	4.3	16
135	Use of Rasâ€Transformed Human Ovarian Surface Epithelial Cells as a Model for Studying Ovarian Cancer. Methods in Enzymology, 2006, 407, 660-676.	0.4	15
136	Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Modern Pathology, 2007, 20, 1078-1084.	2.9	14
137	Renal cell carcinoma metastatic to the ovary or fallopian tube: a clinicopathological study of 9 cases. Human Pathology, 2016, 51, 96-102.	1.1	14
138	NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget, 2016, 7, 3018-3032.	0.8	14
139	Loss of p53 in stromal fibroblasts promotes epithelial cell invasion through redox-mediated ICAM1 signal. Free Radical Biology and Medicine, 2013, 58, 1-13.	1.3	13
140	Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget, 2016, 7, 72845-72859.	0.8	13
141	Expression of B7â€“H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Human Pathology, 2021, 113, 20-27.	1.1	13
142	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports, 2019, 9, 17589.	1.6	12
143	Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells?. Annals of Diagnostic Pathology, 2020, 46, 151505.	0.6	12
144	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers, 2022, 14, 2498.	1.7	12

#	Article	IF	Citations
145	Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Scientific Reports, 2020, 10, 520.	1.6	9
146	Precursors in the ovarian stroma: another pathway to explain the origin of ovarian serous neoplasms. Human Pathology, 2022, 127, 136-145.	1.1	7
147	Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecologic Oncology Reports, 2017, 20, 93-96.	0.3	5
148	Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1â€“Mediated Cell Death in Uterine Cancer. Molecular Cancer Therapeutics, 2020, 19, 1943-1954.	1.9	5
149	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3545-3555.	1.2	5
150	Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Modern Pathology, 2004, 17, 75-80.	2.9	5
151	Meta-analysis demonstrates no association between p16 ink4a promoter methylation and epithelial ovarian cancer. Archives of Gynecology and Obstetrics, 2017, 295, 697-704.	0.8	4
152	Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Reports, 2022, 38, 110301.	2.9	4
153	A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers, 2021, 13, 704.	1.7	3
154	Mucinous borderline tumor involving fallopian tube: case report and review of the literature. International Journal of Clinical and Experimental Pathology, 2013, 6, 962-5.	0.5	3
155	Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. International Journal of Oncology, 2004, 24, 879-84.	1.4	3
156	Sheep stromalâ€epithelial cell interactions and ovarian tumor progression. International Journal of Cancer, 2007, 121, 2346-2354.	2.3	2
157	Ovarian Epithelial Carcinogenesis. , 2019, , 121-139.		2
158	Gastric-type mucinous adenocarcinoma of the uterine cervix with neoadjuvant therapy mimicking clear cell carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 11798-803.	0.5	2
159	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
160	Transformation of the Human Ovarian Surface Epithelium with Genetically Defined Elements. Methods in Molecular Biology, 2013, 1049, 377-392.	0.4	0